Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Moves To Curb Avastin's Approval For Breast Cancer
The Food and Drug administration on Thursday revoked its approval of Avastin for the treatment of breast cancer. The agency's action, based on findings that did not confirm that the medicine helped patients with this disease, has drawn criticism from patients and politicians.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
